Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panelBhavana Pothuri, Premal Thaker, Adrienne Moore, Rosa Espinosa, Kara Medina, Deborah Collyar, Kathleen Lutz, Mihaela C Munteanu, Brian Slomovitz
13 September 2024
Association between Silva pattern-based classification and endocervical adenocarcinoma: a systematic review and meta-analysisMengmeng Chen, Ling Han, Yisi Wang, Yali Chen, Ai Zheng
13 September 2024
Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE studyPremal H Thaker, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda V Kalilani, Jeanne M Schilder, Jean A Hurteau, Amanda K Golembesky
7 September 2024
Efficacy of locoregional analgesic techniques after laparotomy for gynecologic cancer: a systematic reviewLieke A Dhondt, Maya S Vereen, Ralf L O van de Laar, Robert-Jan Stolker, Maaike Dirckx, Heleen J van Beekhuizen
9 August 2024
Investigating age and ethnicity as novel high-risk phenotypes in mucinous ovarian cancer: retrospective study in a multi-ethnic populationTejumola Olaoye, Ayushi ‐, William Boyle, Anthony Williams, Raji Ganesan, Kamana Subba, Akanksha Goyal, Elaine Leung, Rahul Chowdhary, Jennifer Pascoe, Sarah Williams, Jason Yap, Janos Balega, Satyam Kumar, Kavita SinghSee the full list of authors
11 June 2024
A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on a PARP inhibitor as first-line maintenance therapy: the SOCCER-P study (KGOG 3067/JGOG 3036/APGOT-OV11)Hyun-Woong Cho, Hee-Seung Kim, Jeong-Yeol Park, Yoo Young Lee, Myong Cheol Lim, Sung-Jong Lee, Kyung-Jin Min, Kyung Jin Eoh, Kwang Beom Lee, Min Kyu Kim, Jae Yun Song, Seung-Hyuk Shim, Yong Il Ji, Yong-Joong Song, Suk-Joon ChangSee the full list of authors
20 August 2024
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and EuropeKathleen N Moore, Mansoor R Mirza, Charlie Gourley, Sandro Pignata, Domenica Lorusso, Bradley J Monk, Jalid Sehouli, Jeanne M Schilder, Nathalie D'Esquermes, Antonio González-Martín
20 August 2024
Sarcopenia shortens overall survival of patients with platinum-resistant recurrent ovarian cancer: inverse probability of treatment-weighting analysisMasahiro Aichi, Sho Hasegawa, Satoru Shinoda, Yukio Suzuki, Natsuko Kamiya, Yumi Ishidera, Yuichi Imai, Etsuko Miyagi, Taichi Mizushima
5 August 2024
Management of endometrial cancer in Latin America: raising the standard of care and optimizing outcomesAlbano Blanco, Angélica Nogueira-Rodrigues, Filomena Marino Carvalho, Gonzalo Giornelli, Mansoor Raza Mirza
2 May 2024
ENGOT-EN20/GOG-3083/XPORT-EC-042 – A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial designIgnace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, Bradley J Monk, Thomas Herzog, David Cibula, Nicoletta Colombo, Bhavana Pothuri, Jalid Sehouli, Jacob Korach, Joyce Barlin, Christos A Papadimitriou, Toon van Gorp, Debra Richardson, Michael McCarthySee the full list of authors
16 April 2024